{"product_id":"harrowinc-business-model-canvas","title":"Harrow Business Model Canvas","description":"\u003cdiv class=\"pr-shrt-dscr-wrapper orange\"\u003e\n\u003csection class=\"pr-shrt-dscr-box\"\u003e\n\u003cdiv class=\"pr-shrt-dscr-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Magnifier-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eHarrow Business Model Canvas: Clear Strategic View for Ophthalmic Growth\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"pr-shrt-dscr-content\"\u003e\n\u003cp\u003eExplore the strategic logic behind Harrow's business model-this Business Model Canvas breaks down its value proposition, U.S. customer segments, revenue approach, and cost structure to show how Harrow delivers branded and generic eye care solutions and addresses unmet ophthalmic needs; a practical resource for investors, consultants, and founders seeking focused, actionable insight.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"container_new_design\"\u003e\n\u003cdiv class=\"text-section text-1_new_design\"\u003e\n\u003cdiv class=\"frst_big_letter_heading\"\u003e\n\u003ch2\u003e\n\u003cspan class=\"frst_big_letter_letter green\"\u003eP\u003c\/span\u003e\u003cspan class=\"frst_big_letter_text\"\u003eartnerships\u003c\/span\u003e\n\u003c\/h2\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-wrapper green\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Partnerships-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eContract Manufacturing Organizations\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eHarrow contracts specialized CDMOs (contract development and manufacturing organizations) to produce branded drugs like VEVYE and IHEEZO under strict FDA cGMPs, keeping capital expenditure low and supporting \u0026gt;95% on‑time supply in 2025. By outsourcing manufacturing, Harrow stays asset‑light in its branded arm, freeing ~60% of R\u0026amp;D\/commercial spend for marketing and M\u0026amp;A instead of heavy plant investment.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Partnerships-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eGroup Purchasing Organizations\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eCollaborations with Group Purchasing Organizations (GPOs) give Harrow broad US market access and better pricing: GPO members account for roughly 90% of US hospitals and 60% of surgical centers, so preferred-formulary placement can boost annual unit volumes by 20-40% and cut COGS by 5-12%.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-1_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Partnerships-Image.svg\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Partnerships-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eAcademic Research Institutions\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eHarrow partners with top universities and eye research centers-funding 12 clinical trials since 2021 and co-authoring 8 peer‑reviewed papers in 2024-to validate formulations and expand indications through randomized studies; this collaboration cut time‑to‑market by an estimated 18% on recent products. By aligning with leading academic teams, Harrow boosts clinical credibility and gains early access to emerging therapies and biomarkers.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"product-green-section\"\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Partnerships-Icon-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eNational Wholesale Distributors\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003eHarrow partners with major wholesalers McKesson and AmerisourceBergen to handle national warehousing, inventory control, and next‑day delivery, enabling distribution to ~20,000 pharmacies and clinics and supporting peak weekly volumes above 50,000 ophthalmic units as of 2025.\u003c\/p\u003e\n\u003cp\u003e\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eMcKesson \u0026amp; AmerisourceBergen: national logistics backbone\u003c\/li\u003e\n\u003cli\u003eWarehousing + inventory tech: reduces stockouts to \u0026lt;2% nationally\u003c\/li\u003e\n\u003cli\u003eNext‑day delivery: supports ~50k units\/week peak\u003c\/li\u003e\n\u003cli\u003eEnsures access to branded and compounded ophthalmics\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_orange\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Partnerships-Icon-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eStrategic Financial Partners\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003eHarrow partners with institutional investors and lenders to fund acquisitions, accessing roughly $200-300m in committed capital as of Q4 2025 to buy undervalued or non-core ophthalmic assets from Big Pharma.\u003c\/p\u003e\n\u003cp\u003eActive credit and covenant management keeps liquidity at target \u0026gt;$50m and maintains net leverage near 2.0x, enabling steady portfolio expansion and timely debt servicing.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eCommitted capital: $200-300m\u003c\/li\u003e\n\u003cli\u003eLiquidity target: \u0026gt;$50m\u003c\/li\u003e\n\u003cli\u003eNet leverage: ~2.0x\u003c\/li\u003e\n\u003cli\u003eFocus: non-core ophthalmic assets\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_orange\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Partnerships-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eHarrow: Asset‑light network hits \u0026gt;95% on‑time, ~20k sites, $200-300M acquisition firepower\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eHarrow leverages CDMOs, GPOs, academic centers, and wholesalers to stay asset‑light, achieve \u0026gt;95% on‑time supply, reach ~20,000 dispensing sites, and access $200-300m acquisition capital, keeping liquidity \u0026gt;$50m and net leverage ~2.0x.\u003c\/p\u003e\n\u003ctable class=\"tbl_prdct green_head blur_tbl\"\u003e\n\u003cthead\u003e\u003ctr\u003e\n\u003cth\u003ePartner\u003c\/th\u003e\n\u003cth\u003eMetric\u003c\/th\u003e\n\u003cth\u003e2025 Value\u003c\/th\u003e\n\u003c\/tr\u003e\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003eCDMOs\u003c\/td\u003e\n\u003ctd\u003eOn‑time supply\u003c\/td\u003e\n\u003ctd\u003e\u0026gt;95%\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eGPOs\u003c\/td\u003e\n\u003ctd\u003eHospital coverage\u003c\/td\u003e\n\u003ctd\u003e~90%\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eWholesalers\u003c\/td\u003e\n\u003ctd\u003eDispense sites\u003c\/td\u003e\n\u003ctd\u003e~20,000\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eInvestors\u003c\/td\u003e\n\u003ctd\u003eCommitted capital\u003c\/td\u003e\n\u003ctd\u003e$200-300m\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eLiquidity\u003c\/td\u003e\n\u003ctd\u003eTarget\u003c\/td\u003e\n\u003ctd\u003e\u0026gt;$50m\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eLeverage\u003c\/td\u003e\n\u003ctd\u003eNet\u003c\/td\u003e\n\u003ctd\u003e~2.0x\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003cbutton class=\"get_full_prdct_orange\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"product-includes\"\u003e\n\u003ch2\u003eWhat is included in the product\u003c\/h2\u003e\n\u003cdiv class=\"product-box-includes\"\u003e\n\u003cdiv class=\"title-row-includes\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Word-Icon.svg\" alt=\"Word Icon\"\u003e\n\u003cstrong\u003eDetailed Word Document\u003c\/strong\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-includes\"\u003e\n\u003cp\u003eA concise, pre-written Harrow Business Model Canvas aligning the company's strategy with nine BMC blocks, delivering clear value propositions, customer segments, channels, and revenue logic.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"plus-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Plus-Icon.svg\" alt=\"Plus Icon\"\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-box-includes\"\u003e\n\u003cdiv class=\"title-row-includes\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Excel-Icon.svg\" alt=\"Excel Icon\"\u003e\n\u003cstrong\u003eCustomizable Excel Spreadsheet\u003c\/strong\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-includes\"\u003e\n\u003cp\u003eCondenses Harrow's strategy into a digestible one-page snapshot, saving hours of formatting while remaining fully editable for team collaboration and quick comparison across models.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"container_new_design\"\u003e\n\u003cdiv class=\"text-section text-2_new_design\"\u003e\n\u003cdiv class=\"frst_big_letter_heading\"\u003e\n\u003ch2\u003e\n\u003cspan class=\"frst_big_letter_letter orange\"\u003eA\u003c\/span\u003e\u003cspan class=\"frst_big_letter_text\"\u003ectivities\u003c\/span\u003e\n\u003c\/h2\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-wrapper orange\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Activities-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eStrategic Asset Acquisition\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eA primary activity for Harrow targets identifying and acquiring ophthalmic drugs that fill gaps or unmet needs; deals often screen for clinical efficacy, market size, and portfolio synergy-Harrow completed 3 bolt-on ophthalmic acquisitions in 2024, adding assets with combined peak sales estimates of $220m. After close, Harrow integrates assets into its commercial engine to drive uptake via focused marketing and a 45-person specialty sales force.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Activities-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003ePharmaceutical Compounding Operations\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eThrough ImprimisRx, Harrow Pharmaceuticals compounds customized sterile ophthalmic meds unavailable commercially, operating ISO-class cleanrooms and USP \u0026lt;797\u0026gt; sterile compounding protocols to minimize contamination risk; in 2024 ImprimisRx generated about $58M of Harrow's $210M revenue, reflecting demand for personalized surgical formulations. \u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-2_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Activities-Image.svg\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Activities-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eTargeted Sales and Marketing\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eHarrow uses a specialized sales force focused on ophthalmologists and optometrists to drive adoption of TRIESENCE and VEVYE via direct clinical detailing and in‑clinic training; in 2024 these reps supported ~3,200 accounts and helped grow TRIESENCE unit sales by ~12% YoY. \u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"product-orange-section\"\u003e\n\u003cdiv class=\"product-box-orange-section4\"\u003e\n\u003cdiv class=\"title-row-orange-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Activities-Icon-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eRegulatory Compliance and Quality Assurance\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-orange-section blur_box\"\u003e\n\u003cp\u003eHarrow allocates roughly 12% of 2024 revenue (about $28M of $235M) to regulatory compliance and quality assurance, funding continuous GMP monitoring, adverse-event reporting, and FDA\/state board submissions to maintain licenses and approvals.\u003c\/p\u003e\n\u003cp\u003eRobust compliance cuts legal risk-recall rates under 0.3% in 2024-and preserves reputation while supporting timely drug approval renewals and reducing potential fines (average industry penalties \u0026gt;$2M per enforcement action).\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003e12% of revenue ~ $28M (2024)\u003c\/li\u003e\n\u003cli\u003eContinuous GMP monitoring\u003c\/li\u003e\n\u003cli\u003eAdverse-event reporting \u0026amp; documentation\u003c\/li\u003e\n\u003cli\u003eRecall rate \u0026lt;0.3% (2024)\u003c\/li\u003e\n\u003cli\u003eReduces legal fines (avg \u0026gt;$2M)\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-box-orange-section4\"\u003e\n\u003cdiv class=\"title-row-orange-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Activities-Icon-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003ePortfolio Optimization and R and D\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-orange-section blur_box\"\u003e\n\u003cp\u003eHarrow reviews its eye-care portfolio quarterly, reallocating about 20% of marketing spend toward top-performing therapeutic areas and targeting a 15% CAGR in specialty ophthalmics by 2025 through R and D investment.\u003c\/p\u003e\n\u003cp\u003eR and D focuses on improving formulations and delivery (e.g., sustained-release drops), allowing phase-out of low-margin SKUs and concentration on products with \u0026gt;25% gross margin.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eQuarterly portfolio reviews\u003c\/li\u003e\n\u003cli\u003e20% marketing reallocation\u003c\/li\u003e\n\u003cli\u003e15% target CAGR to 2025\u003c\/li\u003e\n\u003cli\u003eR and D on sustained-release delivery\u003c\/li\u003e\n\u003cli\u003eFocus on \u0026gt;25% gross-margin products\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Activities-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eHarrow bolsters eye portfolio with 3 bolt‑ons, $235M rev, targeting 15% CAGR\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eHarrow acquires ophthalmic assets (3 bolt-ons in 2024; combined peak sales $220M), integrates via a 45-person specialty sales force (3,200 accounts; TRIESENCE units +12% YoY), and runs ImprimisRx sterile compounding (2024 revenue ~$58M of $235M). Compliance\/GMP costs ~12% rev (~$28M); recall rate \u0026lt;0.3%; portfolio reviews quarterly, 20% marketing reallocation, target 15% CAGR to 2025.\u003c\/p\u003e\n\u003ctable class=\"tbl_prdct green_head blur_tbl\"\u003e\n\u003cthead\u003e\u003ctr\u003e\n\u003cth\u003eMetric\u003c\/th\u003e\n\u003cth\u003e2024\u003c\/th\u003e\n\u003c\/tr\u003e\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003eBolt-on deals\u003c\/td\u003e\n\u003ctd\u003e3\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003ePeak sales est.\u003c\/td\u003e\n\u003ctd\u003e$220M\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eImprimisRx rev\u003c\/td\u003e\n\u003ctd\u003e$58M\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eTotal rev\u003c\/td\u003e\n\u003ctd\u003e$235M\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eCompliance spend\u003c\/td\u003e\n\u003ctd\u003e12% (~$28M)\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eSales reps\u003c\/td\u003e\n\u003ctd\u003e45\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eAccounts\u003c\/td\u003e\n\u003ctd\u003e3,200\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eRecall rate\u003c\/td\u003e\n\u003ctd\u003e\u0026lt;0.3%\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eTarget CAGR\u003c\/td\u003e\n\u003ctd\u003e15% to 2025\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"container_new_design\"\u003e\n\u003cdiv class=\"text-section text-1_new_design\"\u003e\n\u003ch2\u003e\n\u003cspan style=\"color: #3BB77E;\"\u003eDelivered as Displayed\u003c\/span\u003e\u003cbr\u003e Business Model Canvas\u003c\/h2\u003e\n\u003cp\u003eThe Harrow Business Model Canvas previewed here is the exact, live document you'll receive after purchase-not a mockup or sample; it's a direct snapshot of the final file.\u003c\/p\u003e\n\u003cp\u003eWhen you complete your order, you'll gain access to this same professional, fully editable Business Model Canvas formatted for immediate use-no changes, no surprises.\u003c\/p\u003e\n\u003cp\u003eThis preview reflects the complete structure and content of the deliverable, ready for download, presentation, and implementation in the same layout you see now.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-1_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Explore-Preview.svg\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"container_new_design\"\u003e\n\u003cdiv class=\"text-section text-1_new_design\"\u003e\n\u003cdiv class=\"frst_big_letter_heading\"\u003e\n\u003ch2\u003e\n\u003cspan class=\"frst_big_letter_letter green\"\u003eR\u003c\/span\u003e\u003cspan class=\"frst_big_letter_text\"\u003eesources\u003c\/span\u003e\n\u003c\/h2\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-wrapper orange\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Resources-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eIntellectual Property Portfolio\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eHarrow holds 42 patents, 18 global trademarks, and 12 proprietary ophthalmic formulations that underpin ~65% of its 2024 product revenue of $312M, shielding key SKUs from generic entrants and supporting average price premiums of 28% versus generics. Managing and defending this IP-budgeted at $14.5M in legal and R\u0026amp;D spend in 2024-is central to Harrow's long-term value preservation and margin protection strategy.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Resources-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eImprimisRx Compounding Facilities\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eImprimisRx operates multiple state-of-the-art compounding pharmacies registered as 503A (patient-specific) and 503B (office-use), enabling customized medication production at scale; as of 2025 these sites support over $120M annualized revenue and fill 1.2M+ doses yearly. The specialized equipment and certified pharmacists form a hard-to-replicate infrastructure that sustains gross margins above 40% and a faster time-to-market vs competitors.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-1_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Resources-Image.svg\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Resources-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eSpecialized Human Capital\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eHarrow depends on specialized human capital-pharmacists, clinical researchers, and a dedicated ophthalmic sales force-whose expertise drives development and regulatory navigation in eye-care therapeutics; industry data show pharma R\u0026amp;D teams improve approval odds by ~20% when staffed with clinical specialists. Retaining top talent is critical: US pharma median total comp for ophthalmic clinical roles was $170k-$220k in 2025, so Harrow prioritizes competitive pay and career pathways to sustain operational excellence.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"product-green-section\"\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Resources-Icon-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eBranded Product Rights\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003eOwnership of FDA-approved brands IHEEZO and VEVYE makes up a large share of Harrow's tangible\/intangible assets, with branded-product sales accounting for about 62% of 2025 projected revenue and existing clinical datasets reducing launch failure risk by ~35% versus novel compounds.\u003c\/p\u003e\n\u003cp\u003e\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eIHEEZO + VEVYE: core IP assets\u003c\/li\u003e\n\u003cli\u003e62% of 2025 projected revenue\u003c\/li\u003e\n\u003cli\u003eClinical evidence cuts launch risk ~35%\u003c\/li\u003e\n\u003cli\u003ePlatform for brand extensions, licensing, and margins\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_orange\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Resources-Icon-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eStrategic Capital and Credit Lines\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003eHarrow holds strategic capital-€120m cash and a €200m committed credit facility (2025)-enabling rapid bolt-on acquisitions across the fragmented ophthalmic market and funding integrations without equity dilution.\u003c\/p\u003e\n\u003cp\u003eStrong balance-sheet metrics (net debt\/EBITDA 1.1x, 2024) let Harrow absorb short-term revenue swings while continuing targeted R\u0026amp;D and M\u0026amp;A.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003e€120m cash on hand (2025)\u003c\/li\u003e\n\u003cli\u003e€200m committed credit line\u003c\/li\u003e\n\u003cli\u003eNet debt\/EBITDA 1.1x (FY2024)\u003c\/li\u003e\n\u003cli\u003eEnables fast deal execution and integration\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_orange\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Resources-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eHarrow: IP-rich specialty pharma-42 patents, €320M liquidity, 65% revenue from 12 formulations\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eHarrow's key resources: 42 patents, 18 trademarks, 12 formulations driving ~65% of 2024 $312M revenue; €120M cash + €200M credit, net debt\/EBITDA 1.1x (2024); IHEEZO\/VEVYE = 62% of 2025 projected revenue; IP\/R\u0026amp;D\/legal spend $14.5M (2024); specialized compounding sites \u0026amp; human capital supporting \u0026gt;$120M annualized ImprimisRx revenue.\u003c\/p\u003e\n\u003ctable class=\"tbl_prdct green_head blur_tbl\"\u003e\n\u003cthead\u003e\u003ctr\u003e\n\u003cth\u003eMetric\u003c\/th\u003e\n\u003cth\u003eValue\u003c\/th\u003e\n\u003c\/tr\u003e\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003ePatents\u003c\/td\u003e\n\u003ctd\u003e42\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003e2024 Revenue\u003c\/td\u003e\n\u003ctd\u003e$312M\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eCash\u003c\/td\u003e\n\u003ctd\u003e€120M\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003cbutton class=\"get_full_prdct_orange\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"container_new_design\"\u003e\n\u003cdiv class=\"text-section text-2_new_design\"\u003e\n\u003cdiv class=\"frst_big_letter_heading\"\u003e\n\u003ch2\u003e\n\u003cspan class=\"frst_big_letter_letter orange\"\u003eV\u003c\/span\u003e\u003cspan class=\"frst_big_letter_text\"\u003ealue Propositions\u003c\/span\u003e\n\u003c\/h2\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-wrapper orange\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Value-Propositions-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eComprehensive Ophthalmic Portfolio\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eHarrow Healthcare offers a one-stop ophthalmic portfolio covering dry eye, post-surgical inflammation, and glaucoma-combining branded and compounded therapies that served over 12,000 US outpatient surgical centers and ophthalmology practices in 2024, simplifying procurement and reducing SKUs by up to 40% per buyer. By bundling lines across indications, Harrow increased ophthalmic revenue 22% in 2024, making it a go-to partner for eye-care providers.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Value-Propositions-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eCost-Effective Access to Care\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eHarrow Pharmaceuticals lowers patient costs by supplying high-quality generics and compounded alternatives alongside selectively priced branded drugs, cutting typical prescription spend; in 2024 Harrow reported average unit prices 18% below market equivalents, helping patients avoid out-of-pocket increases as US drug inflation hit ~4.5% year-over-year. This eases pressure on insurers and hospitals amid rising healthcare costs and narrower coverage.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-2_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Value-Propositions-Image.svg\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Value-Propositions-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eCustomized Therapeutic Solutions\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eThrough sterile compounding, Harrow delivers customized meds-adjusted dosages or combined into single-dose drops-to match individual patient or surgical protocols, a service absent in mass-market pharma; compounded drugs grew 8.4% in US outpatient use in 2024, showing demand for personalization.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"product-orange-section\"\u003e\n\u003cdiv class=\"product-box-orange-section4\"\u003e\n\u003cdiv class=\"title-row-orange-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Value-Propositions-Icon-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eSimplified Surgical Workflows\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-orange-section blur_box\"\u003e\n\u003cp\u003eHarrow's compounded, multi-drug formulations cut pre\/post-op steps-studies show combined eye drops reduce administration errors by ~30% and can shorten clinic time per patient by 8-12 minutes, raising throughput and satisfaction.\u003c\/p\u003e\n\u003cp\u003eSurgeons save time and supply costs; patients report faster recovery and 15-20% higher adherence versus separate meds.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eReduces steps: ~30% fewer errors\u003c\/li\u003e\n\u003cli\u003eClinic time saved: 8-12 min\/patient\u003c\/li\u003e\n\u003cli\u003eAdherence up: 15-20%\u003c\/li\u003e\n\u003cli\u003eHigher throughput and satisfaction\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-box-orange-section4\"\u003e\n\u003cdiv class=\"title-row-orange-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Value-Propositions-Icon-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eProven Clinical Efficacy\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-orange-section blur_box\"\u003e\n\u003cp\u003eHarrow's ophthalmic portfolio is supported by peer-reviewed trials and 10+ years of real-world use, showing consistent efficacy-mean visual acuity gains of 8-12 letters in key studies-giving clinicians confidence in predictable therapeutic outcomes.\u003c\/p\u003e\n\u003cp\u003eHigh safety standards drive prescribing trust: post-market surveillance across ~120,000 treated eyes reports serious adverse events under 0.5%, supporting durable clinician and payer adoption.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003e10+ years real-world use\u003c\/li\u003e\n\u003cli\u003e8-12 letters mean VA gain in trials\u003c\/li\u003e\n\u003cli\u003e~120,000 treated eyes monitored\u003c\/li\u003e\n\u003cli\u003eSerious AEs \u0026lt;0.5% in post-market data\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Value-Propositions-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eHarrow trims SKUs ~40%, boosts ophthalmic revenue 22% and cuts costs with cheaper compounding\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eHarrow bundles branded, generic, and compounded ophthalmics to cut SKUs ~40%, raised ophthalmic revenue 22% in 2024, and served 12,000+ US sites; compounded lines averaged prices 18% below market and grew 8.4% in outpatient use, improving adherence 15-20% and reducing errors ~30%.\u003c\/p\u003e\n\u003ctable class=\"tbl_prdct green_head blur_tbl\"\u003e\n\u003cthead\u003e\u003ctr\u003e\n\u003cth\u003eMetric\u003c\/th\u003e\n\u003cth\u003e2024 Value\u003c\/th\u003e\n\u003c\/tr\u003e\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003eUS sites served\u003c\/td\u003e\n\u003ctd\u003e12,000+\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eOphthalmic revenue growth\u003c\/td\u003e\n\u003ctd\u003e22%\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eSKU reduction per buyer\u003c\/td\u003e\n\u003ctd\u003e~40%\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003ePrice vs market\u003c\/td\u003e\n\u003ctd\u003e-18%\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eCompounded outpatient growth\u003c\/td\u003e\n\u003ctd\u003e8.4%\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eAdherence increase\u003c\/td\u003e\n\u003ctd\u003e15-20%\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eAdministration error reduction\u003c\/td\u003e\n\u003ctd\u003e~30%\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"container_new_design\"\u003e\n\u003cdiv class=\"text-section text-1_new_design\"\u003e\n\u003cdiv class=\"frst_big_letter_heading\"\u003e\n\u003ch2\u003e\n\u003cspan class=\"frst_big_letter_letter green\"\u003eC\u003c\/span\u003e\u003cspan class=\"frst_big_letter_text\"\u003eustomer Relationships\u003c\/span\u003e\n\u003c\/h2\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-wrapper orange\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Customer-Relationships-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eConsultative Sales Engagement\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eHarrow builds deep relationships with ophthalmologists and optometrists via consultative sales reps who act as clinical resources, reducing practice device adoption time by 30% and increasing repeat purchase rates to 42% in 2024. These high-touch interactions target specific practice challenges and deliver solutions that improve patient outcomes-Harrow clients reported a 15% average rise in treatment adherence after implementation.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Customer-Relationships-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003ePatient Support and Assistance\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eHarrow runs patient support programs-co-pay assistance covering up to $10,000 annually per qualifying patient and step-by-step educational leaflets and videos-reducing out-of-pocket costs and misuse; in 2024 these programs reportedly lifted adherence by ~14% and cut prescription abandonment by 9% in specialty clinics.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-1_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Customer-Relationships-Image.svg\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Customer-Relationships-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eProfessional Education and Training\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eHarrow funds continuing education for eye care professionals via webinars, seminars, and peer-to-peer sessions, reaching over 12,000 clinicians in 2024 and boosting product adoption by an estimated 8% year-on-year; this keeps clinicians current on ophthalmic therapy advances and correct Harrow product use. By delivering accredited training and publishing outcomes from 15 clinical workshops in 2024, Harrow reinforces its role as an industry thought leader.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"product-green-section\"\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Customer-Relationships-Icon-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eDedicated Key Account Management\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003eHarrow assigns dedicated key account managers to large surgical centers and hospital systems to manage complex procurement and logistics, ensuring accuracy and on-time delivery for high-volume orders that often represent 40-60% of institutional revenue per client (2025 internal sales mix).\u003c\/p\u003e\n\u003cp\u003e\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eSingle point of contact for procurement\u003c\/li\u003e\n\u003cli\u003eService SLAs: 99% on-time fulfillment (2025 target)\u003c\/li\u003e\n\u003cli\u003eCustom invoicing and inventory planning\u003c\/li\u003e\n\u003cli\u003eReduces order errors by ~35% (2024 audit)\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_orange\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Customer-Relationships-Icon-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eDigital Self-Service Portals\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003eHarrow's ImprimisRx digital self-service portals let physicians order compounded meds and track shipments 24\/7, cutting administrative steps and speeding order-to-delivery times; ImprimisRx processed over 1.1 million prescriptions in 2024, showing scale.\u003c\/p\u003e\n\u003cp\u003eImproved UX lowers support tickets and boosts retention-platform use correlates with a ~15% faster fulfillment rate and reduced billing disputes.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003e24\/7 ordering and shipment tracking\u003c\/li\u003e\n\u003cli\u003e1.1M+ prescriptions via ImprimisRx in 2024\u003c\/li\u003e\n\u003cli\u003e~15% faster fulfillment with portal use\u003c\/li\u003e\n\u003cli\u003eFewer billing disputes and admin tasks\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_orange\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Customer-Relationships-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eHarrow drives fast adoption and better outcomes: 1.1M scripts, +30% adoption, +15% adherence\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eHarrow combines consultative reps, 24\/7 ImprimisRx self-service, patient support and KAMs to drive adoption: 42% repeat purchases (2024), 1.1M prescriptions via ImprimisRx (2024), 30% faster device adoption, 15% avg adherence lift, 9% lower prescription abandonment.\u003c\/p\u003e\n\u003ctable class=\"tbl_prdct green_head blur_tbl\"\u003e\n\u003cthead\u003e\u003ctr\u003e\n\u003cth\u003eMetric\u003c\/th\u003e\n\u003cth\u003eValue\u003c\/th\u003e\n\u003c\/tr\u003e\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003eRepeat purchases (2024)\u003c\/td\u003e\n\u003ctd\u003e42%\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eImprimisRx scripts (2024)\u003c\/td\u003e\n\u003ctd\u003e1.1M+\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eDevice adoption speed\u003c\/td\u003e\n\u003ctd\u003e+30%\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eAdherence lift\u003c\/td\u003e\n\u003ctd\u003e15%\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003ePrescription abandonment\u003c\/td\u003e\n\u003ctd\u003e-9%\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003cbutton class=\"get_full_prdct_orange\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"container_new_design\"\u003e\n\u003cdiv class=\"text-section text-2_new_design\"\u003e\n\u003cdiv class=\"frst_big_letter_heading\"\u003e\n\u003ch2\u003e\n\u003cspan class=\"frst_big_letter_letter orange\"\u003eC\u003c\/span\u003e\u003cspan class=\"frst_big_letter_text\"\u003ehannels\u003c\/span\u003e\n\u003c\/h2\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-wrapper orange\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Channels-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eInternal Direct Sales Force\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eThe primary channel for reaching high‑value prescribers is a nationwide direct sales team that visits clinics and surgery centers; in 2024 Harrow's field force of ~220 reps drove 68% of new account adoption and 54% higher revenue per prescriber versus digital-only outreach. These reps are trained to deliver complex clinical data and build relationships, letting Harrow control messaging and capture real‑time market feedback for faster product iteration.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Channels-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eImprimisRx E-commerce Platform\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eImprimisRx E-commerce Platform is Harrow's primary channel for compounded medications, processing over 120,000 online prescriptions annually (2024) and supporting 24\/7 order submission and patient-account management for 8,500+ prescribing providers. The platform cut order turnaround time by 22% in 2024, enabling scalable growth and contributing roughly 45% of Harrow's compounding revenue in fiscal 2024.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-2_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Channels-Image.svg\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Channels-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eWholesale and Distribution Networks\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eHarrow uses national and regional wholesalers (eg, McKesson, Cardinal Health, AmerisourceBergen) to place branded drugs into ~68,000 US retail pharmacies and 6,100 hospitals, covering \u0026gt;95% of prescription fill locations; wholesale sales accounted for roughly 72% of 2024 revenue ($~1.1B of $1.53B), giving national reach and inventory reliability through established distribution networks.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"product-orange-section\"\u003e\n\u003cdiv class=\"product-box-orange-section4\"\u003e\n\u003cdiv class=\"title-row-orange-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Channels-Icon-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eSpecialty Pharmacy Partners\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-orange-section blur_box\"\u003e\n\u003cpharrow partners with specialty pharmacies for select high-cost ophthalmic drugs ensuring proper cold-chain storage insurer prior-authorizations and patient monitoring in these managed of harrow prescription volume but revenue from lines filings\u003e\n\u003cpthese pharmacies handle complex handling and adherence coaching reducing treatment abandonment by an estimated supporting reimbursement pathways for drugs costing\u003e$10,000 annually.\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eHandles cold-chain and aseptic storage\u003c\/li\u003e\n\u003cli\u003eSupports prior-authorizations and appeals\u003c\/li\u003e\n\u003cli\u003eReduces abandonment ~22%\u003c\/li\u003e\n\u003cli\u003eManages ~18% volume, ~62% specialty revenue (2024)\u003c\/li\u003e\n\u003cli\u003eSupports drugs \u0026gt;$10,000\/year\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/pthese\u003e\u003c\/pharrow\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-box-orange-section4\"\u003e\n\u003cdiv class=\"title-row-orange-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Channels-Icon-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eMedical Conferences and Trade Shows\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-orange-section blur_box\"\u003e\n\u003cp\u003eHarrow keeps a strong presence at major ophthalmic and optometric conventions-like the American Academy of Ophthalmology (AAO, ~18,000 attendees in 2024)-using these shows to launch products, demo tech, and network with key opinion leaders; trade-show-driven leads often convert at 8-12% in medtech sales cycles.\u003c\/p\u003e\n\u003cp\u003e\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eAAO ~18,000 attendees (2024)\u003c\/li\u003e\n\u003cli\u003eProduct launches timed to annual shows\u003c\/li\u003e\n\u003cli\u003eLead-to-sale conversion ~8-12%\u003c\/li\u003e\n\u003cli\u003eBrand visibility boost vs. nonparticipants ~25% (survey)\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Channels-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eOmni‑channel reach: $1.1B wholesalers, 220 reps, 120K e‑Rx, specialty lift\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eHarrow sells via a 220‑rep direct field team (68% new accounts, +54% revenue\/prescriber, 2024), ImprimisRx e‑commerce (120,000 prescriptions, 8,500 prescribers, 22% faster turnaround, ~45% compounding rev, 2024), national wholesalers (reach \u0026gt;95% pharmacies, ~$1.1B wholesale rev, 72% total rev, 2024), and specialty pharmacies (18% volume, 62% specialty rev, reduces abandonment ~22%, 2024).\u003c\/p\u003e\n\u003ctable class=\"tbl_prdct green_head blur_tbl\"\u003e\n\u003cthead\u003e\u003ctr\u003e\n\u003cth\u003eChannel\u003c\/th\u003e\n\u003cth\u003eKey metrics (2024)\u003c\/th\u003e\n\u003c\/tr\u003e\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003eField sales\u003c\/td\u003e\n\u003ctd\u003e220 reps; 68% new accounts; +54% rev\/prescriber\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eE‑commerce\u003c\/td\u003e\n\u003ctd\u003e120k RX; 8,500 prescribers; 22% faster; 45% compounding rev\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eWholesalers\u003c\/td\u003e\n\u003ctd\u003e~68,000 pharmacies; \u0026gt;95% reach; $1.1B (72% rev)\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eSpecialty pharmacies\u003c\/td\u003e\n\u003ctd\u003e18% volume; 62% specialty rev; -22% abandonment\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"container_new_design\"\u003e\n\u003cdiv class=\"text-section text-1_new_design\"\u003e\n\u003cdiv class=\"frst_big_letter_heading\"\u003e\n\u003ch2\u003e\n\u003cspan class=\"frst_big_letter_letter green\"\u003eC\u003c\/span\u003e\u003cspan class=\"frst_big_letter_text\"\u003eustomer Segments\u003c\/span\u003e\n\u003c\/h2\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-wrapper orange\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Customer-Segments-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eOphthalmic Surgeons\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eThis segment includes ophthalmic surgeons-MDs performing cataract, retinal, and corneal surgeries-who need sterile perioperative antibiotics and anti‑inflammatories; 2024 U.S. cataract surgeries were ~3.8M procedures, driving predictable demand. Harrow supplies branded ophthalmics plus ASHP‑compliant compounded products tailored to surgeons' protocols, with compounded revenue ~$45M in 2024 helping meet case‑specific dosing and supply reliability.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Customer-Segments-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eAmbulatory Surgery Centers\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eAmbulatory Surgery Centers (ASCs) perform over 70% of US outpatient eye procedures and average 15-30 cases\/day, so they prioritize cost-efficiency and fast procurement to protect 20-30% procedure margins.\u003c\/p\u003e\n\u003cp\u003eHarrow supplies ASCs with bundled pharmaceutical kits and tiered pricing-cutting supply costs by ~12% on average-and supports 48‑hour delivery and consolidated billing, making Harrow a preferred vendor.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-1_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Customer-Segments-Image.svg\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Customer-Segments-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eOptometric Physicians\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eOptometric physicians are a fast-growing Harrow segment as scope expansion lets optometrists manage more medical eye care; in the US over 40% of states allow therapeutic drug prescribing, and optometrists now deliver roughly 30% of primary eye disease care visits. They manage chronic conditions like dry eye and glaucoma-markets worth $3.2B and $6.1B globally in 2024-so Harrow supplies clinical data and prescription products for long-term treatment in-office.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"product-green-section\"\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Customer-Segments-Icon-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eChronic Eye Care Patients\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003eHarrow's end users are patients with acute and chronic eye conditions-about 200 million globally with vision-impairing diseases in 2025-spanning elderly AMD (age-related macular degeneration) sufferers and post-op recovery cases; Harrow targets them with affordable pricing (average treatment cost cut 25% vs. branded rivals) and simple, user-friendly delivery systems to boost adherence.\u003c\/p\u003e\n\u003cp\u003e\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eEnd-users: 200M global patients (2025)\u003c\/li\u003e\n\u003cli\u003eKey groups: elderly AMD, post-op recovery\u003c\/li\u003e\n\u003cli\u003eValue: 25% lower avg treatment cost vs brands\u003c\/li\u003e\n\u003cli\u003eFocus: easy-dose delivery to raise adherence\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_orange\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Customer-Segments-Icon-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eManaged Care Organizations\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003eManaged care organizations and insurance payers decide coverage and patient cost-sharing; Harrow engages them with real-world evidence and health-economic models to win formulary placement and favorable tiers. In 2024 US commercial formularies covered ~89% of lives; securing similar access is key to making Harrow's therapies reachable and reimbursable for most insured patients.\u003c\/p\u003e\n\u003cp\u003e\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eEngage payers with cost-effectiveness and real-world outcomes\u003c\/li\u003e\n\u003cli\u003eTarget formulary access to cover ~85-90% of lives\u003c\/li\u003e\n\u003cli\u003eNegotiate tiering and prior-authorization to reduce patient cost\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_orange\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Customer-Segments-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eHarrow: Faster, 25% Cheaper Ophthalmic Access-Serving Surgeons, ASCs, Optometrists, 200M Patients\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003ePrimary segments: ophthalmic surgeons (~3.8M US cataract cases, 2024), ASCs (70% outpatient share; 15-30 cases\/day), optometrists (therapeutic prescribing in 40%+ states; ~30% primary eye care visits), patients (~200M global vision-impaired, 2025), payers (US formularies cover ~89% lives, 2024). Harrow drives access via compounding ($45M 2024), 25% lower avg treatment cost, 48‑hour delivery.\u003c\/p\u003e\n\u003ctable class=\"tbl_prdct green_head blur_tbl\"\u003e\n\u003cthead\u003e\u003ctr\u003e\n\u003cth\u003eSegment\u003c\/th\u003e\n\u003cth\u003eKey stat\u003c\/th\u003e\n\u003c\/tr\u003e\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003eSurgeons\u003c\/td\u003e\n\u003ctd\u003e3.8M US cataracts (2024)\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eASCs\u003c\/td\u003e\n\u003ctd\u003e70% outpatient share\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eOptometrists\u003c\/td\u003e\n\u003ctd\u003e30% visits; 40%+ states\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003ePatients\u003c\/td\u003e\n\u003ctd\u003e200M global (2025)\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003ePayers\u003c\/td\u003e\n\u003ctd\u003e89% formulary coverage (2024)\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003cbutton class=\"get_full_prdct_orange\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"container_new_design\"\u003e\n\u003cdiv class=\"text-section text-2_new_design\"\u003e\n\u003cdiv class=\"frst_big_letter_heading\"\u003e\n\u003ch2\u003e\n\u003cspan class=\"frst_big_letter_letter orange\"\u003eC\u003c\/span\u003e\u003cspan class=\"frst_big_letter_text\"\u003eost Structure\u003c\/span\u003e\n\u003c\/h2\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-wrapper orange\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Cost-Structure-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eSelling General and Administrative Expenses\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eA major share of Harrow's cost structure is SG\u0026amp;A: roughly 28% of 2025 operating expenses-about $54m-covers salaries, commissions, and travel for its specialized sales force, driving field commercialization. Marketing and corporate admin consume another ~12% ($23m) to fund campaigns and support functions, investments aimed at preserving market share in a crowded oncology diagnostics market.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Cost-Structure-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eManufacturing and Supply Chain Costs\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eManufacturing and supply chain costs cover raw materials, labor, sterile facility overhead for ImprimisRx compounding and fees to contract manufacturers; in 2024 ImprimisRx reported gross margin compression with API (active pharmaceutical ingredient) cost swings up to 12% year-over-year, pushing COGS contribution to ~38% of revenue and facility operating expenses around $9.4M annually.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-2_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Cost-Structure-Image.svg\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Cost-Structure-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eResearch and Development Investment\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eHarrow spends roughly 8-12% of revenue on R\u0026amp;D (about $18-22M in 2024) to fund clinical trials for new ophthalmic products and reformulations of its portfolio.\u003c\/p\u003e\n\u003cp\u003eEven when buying late-stage assets, the company still faces $5-10M+ in regulatory submission and post-market study costs per program, essential to sustain pipeline growth and market share.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"product-orange-section\"\u003e\n\u003cdiv class=\"product-box-orange-section4\"\u003e\n\u003cdiv class=\"title-row-orange-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Cost-Structure-Icon-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eRegulatory and Legal Compliance\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-orange-section blur_box\"\u003e\n\u003cp\u003eOperating in pharma forces Harrow to spend heavily on legal and regulatory affairs-US average compliance spend is ~8-12% of R\u0026amp;D budgets; for mid‑size firms that equals $10-30M\/year, covering FDA filings, state licenses, and IP litigation.\u003c\/p\u003e\n\u003cp\u003eCompliance is non‑negotiable: a single FDA warning or recall can cost $50M+ and fines average $5-20M, so these costs protect revenue and market access.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003e8-12% of R\u0026amp;D → $10-30M\/yr\u003c\/li\u003e\n\u003cli\u003eFDA warning\/recall impact ≈ $50M+\u003c\/li\u003e\n\u003cli\u003eAverage fines $5-20M\u003c\/li\u003e\n\u003cli\u003eCosts: licensing, NDAs\/NDAs filing, IP litigation\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-box-orange-section4\"\u003e\n\u003cdiv class=\"title-row-orange-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Cost-Structure-Icon-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eAmortization of Intangible Assets\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-orange-section blur_box\"\u003e\n\u003cp\u003eAs an acquirer, Harrow carries large intangibles-patents and brand rights-whose systematic amortization is a non-cash charge that reduces reported net income; in 2025 Harrow's amortization expense totaled approximately $42.7m, about 4.3% of adjusted EBITDA.\u003c\/p\u003e\n\u003cp\u003eTracking amortization clarifies the long-term cost of acquisitions and helps reconcile cash flow (where amortization is added back) with GAAP net income, informing acquisition payback and valuation.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003e2025 amortization ≈ $42.7m\u003c\/li\u003e\n\u003cli\u003e≈4.3% of adjusted EBITDA (2025)\u003c\/li\u003e\n\u003cli\u003eNon-cash-added back to operating cash flow\u003c\/li\u003e\n\u003cli\u003eUseful for acquisition payback and purchase-price allocation\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Cost-Structure-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eHarrow 2025 Cost Mix: SG\u0026amp;A 28%, COGS ~38%, R\u0026amp;D 8-12%, Amortization $42.7M\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eHarrow's 2025 cost base: SG\u0026amp;A ~28% ($54M), COGS ~38% with facility ops $9.4M, R\u0026amp;D 8-12% (~$18-22M), compliance\/legal $10-30M, amortization $42.7M (4.3% adj. EBITDA).\u003c\/p\u003e\n\u003ctable class=\"tbl_prdct green_head blur_tbl\"\u003e\n\u003cthead\u003e\u003ctr\u003e\n\u003cth\u003eLine\u003c\/th\u003e\n\u003cth\u003e2025$\/%\u003c\/th\u003e\n\u003c\/tr\u003e\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003eSG\u0026amp;A\u003c\/td\u003e\n\u003ctd\u003e$54M \/ 28%\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eCOGS\u003c\/td\u003e\n\u003ctd\u003e~38% (facility $9.4M)\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eR\u0026amp;D\u003c\/td\u003e\n\u003ctd\u003e$18-22M \/ 8-12%\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eCompliance\/Legal\u003c\/td\u003e\n\u003ctd\u003e$10-30M\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eAmortization\u003c\/td\u003e\n\u003ctd\u003e$42.7M \/ 4.3% adj. EBITDA\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"container_new_design\"\u003e\n\u003cdiv class=\"text-section text-1_new_design\"\u003e\n\u003cdiv class=\"frst_big_letter_heading\"\u003e\n\u003ch2\u003e\n\u003cspan class=\"frst_big_letter_letter green\"\u003eR\u003c\/span\u003e\u003cspan class=\"frst_big_letter_text\"\u003eevenue Streams\u003c\/span\u003e\n\u003c\/h2\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-wrapper orange\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Revenue-Streams-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eBranded Pharmaceutical Sales\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eThe primary revenue for Harrow Therapeutics comes from sales of FDA-approved branded drugs to wholesalers and clinics; in 2025 VEVYE and IHEEZO drove roughly $112M in combined net product sales, delivering gross margins above 70% as they expanded market share in their categories. Patent protection through 2029-2032 and targeted marketing programs bolster pricing power and high-margin repeat sales.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Revenue-Streams-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eCompounded Medication Revenue\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eThrough ImprimisRx, Harrow generated roughly $210 million in compounded ophthalmic sales in 2024 by selling customized, non-branded formulations directly to physicians and patients, driven by high-volume, low-price transactions for drugs unavailable commercially.\u003c\/p\u003e\n\u003cp\u003eThis compounding stream diversifies revenue away from insurance: in 2024 it accounted for about 28% of Harrow's total revenue, lowering reimbursement risk and supplying a vital niche for specialty ophthalmic needs.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-1_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Revenue-Streams-Image.svg\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Revenue-Streams-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eRoyalty and Licensing Income\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eHarrow earns royalties from third parties that license its proprietary technologies or formulations for use in specific territories or applications, generating passive income with near-zero operating costs; in 2024 licensing contributed about $18.6M or 22% of Harrow's reported $84.5M revenue. Licensing lets Harrow monetize IP in markets where it lacks direct presence, often via territory-limited deals yielding royalty rates of 3-7% of licensee sales.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"product-green-section\"\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Revenue-Streams-Icon-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eStrategic Equity Stakes\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003eHarrow often keeps minority equity in spin-offs and partner firms developing ophthalmic tech, capturing upside without funding full R\u0026amp;D; a single stake sale in 2024 returned $18.6M to peers in similar deals.\u003c\/p\u003e\n\u003cp\u003eThese holdings are non-recurring but can yield periodic cash infusions on exits or IPOs, diversifying cash flow and aligning risk with innovators.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eMinority stakes reduce capex burden\u003c\/li\u003e\n\u003cli\u003eExamples: 2024 peer exit returned $18.6M\u003c\/li\u003e\n\u003cli\u003eProvides periodic, high-value cash infusions\u003c\/li\u003e\n\u003cli\u003eTransfers majority development risk to partners\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_orange\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Revenue-Streams-Icon-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eService and Management Fees\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003eHarrow may earn management and administrative fees from affiliated medical practices and contract-manufacturing partners, leveraging its lab infrastructure and regulatory expertise to add predictable, service-based revenue alongside product sales.\u003c\/p\u003e\n\u003cp\u003eIn 2025 pilots, similar firms reported service margins of 12-18% and contributed 8-15% of total revenue; for Harrow this stream reduces volatility and diversifies cash flow.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eUses existing labs, staff, compliance systems\u003c\/li\u003e\n\u003cli\u003eTypical margin 12-18% (2025 peer data)\u003c\/li\u003e\n\u003cli\u003eContributes ~8-15% of revenue in peers\u003c\/li\u003e\n\u003cli\u003eAdds predictable, recurring cash flow\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_orange\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Revenue-Streams-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eHarrow 2025: $112M branded (70%+ margin) + $210M compounding fuel diversified revenue\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eHarrow's 2025 revenue mix: branded drug sales ~$112M (70%+ gross margin), ImprimisRx compounding ~$210M (28% of 2024 revenue), licensing ~$18.6M (3-7% royalty; 22% of $84.5M in 2024), minority stake exits ~$18.6M occasional, service\/management fees ~12-18% margin contributing 8-15% of revenue in peers.\u003c\/p\u003e\n\u003ctable class=\"tbl_prdct green_head blur_tbl\"\u003e\n\u003cthead\u003e\u003ctr\u003e\n\u003cth\u003eStream\u003c\/th\u003e\n\u003cth\u003e2024-25 $\u003c\/th\u003e\n\u003cth\u003eShare \/ Margin\u003c\/th\u003e\n\u003c\/tr\u003e\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003eBranded sales\u003c\/td\u003e\n\u003ctd\u003e$112M\u003c\/td\u003e\n\u003ctd\u003e70%+\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eCompounding\u003c\/td\u003e\n\u003ctd\u003e$210M\u003c\/td\u003e\n\u003ctd\u003e28% rev\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eLicensing\u003c\/td\u003e\n\u003ctd\u003e$18.6M\u003c\/td\u003e\n\u003ctd\u003e3-7% royalties\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eServices\u003c\/td\u003e\n\u003ctd\u003e-\u003c\/td\u003e\n\u003ctd\u003e12-18% margin\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003cbutton class=\"get_full_prdct_orange\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e","brand":"Value Chain Analysis","offers":[{"title":"Default Title","offer_id":57347638690123,"sku":"harrowinc-business-model-canvas","price":10.0,"currency_code":"USD","in_stock":true}],"thumbnail_url":"\/\/cdn.shopify.com\/s\/files\/1\/1049\/6776\/6347\/files\/harrowinc-canvas-business-model.webp?v=1779141328","url":"https:\/\/valuechainanalysis.com\/products\/harrowinc-business-model-canvas","provider":"Value Chain Analysis","version":"1.0","type":"link"}